Bictegravir

Bictegravir Impurities

Bictegravir is an integrase strand transfer inhibitor (INSTI) used in combination therapy for HIV-1 infection. Its impurity profile includes structurally related analogs, residual solvents, and degradation products formed under stress conditions such as hydrolysis, oxidation, and photolysis. Degradation pathways typically involve oxidative breakdown of the heteroaryl rings, hydrolytic cleavage of amide bonds, and rearrangement of the trifluoromethyl-substituted moieties. These impurities may affect the drug’s potency, stability, and safety. All impurities are structurally characterized and qualified in accordance with ICH guidelines for toxicological assessment and analytical validation.

Bictegravir EP Impurities

Pharmacopeial and non-pharmacopeial Bictegravir impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and long-term stability studies. EP traceable materials are supplied with validated analytical data, including purity, structural confirmation, and spectral characterization.

Bictegravir Related Compounds

Structurally related compounds and synthetic analogs associated with Bictegravir are included for use in impurity identification, toxicological qualification, and regulatory submission. These related substances are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations. They are essential for understanding the impurity profile and ensuring compliance with regulatory limits.

Bictegravir Impurity Reference Standards

Bictegravir impurity reference standards are provided with validated analytical data, including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.